THINK DIFFERENTLY
ABOUT DRY EYE DISEASE

WELCOME

Think differently about dry eye disease and how EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% fits into your practice.  EYSUVIS is the first and only FDA-approved corticosteroid for the short-term treatment of dry eye signs and symptoms.

INDICATION 
EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. 

Contraindication
EYSUVIS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. 

​​​​​​​See additional Important Safety Information below.

UPCOMING WEBINARS

IMPORTANT SAFETY INFORMATION 

Warnings and Precautions: 

Delayed Healing and Corneal Perforation: Topical corticosteroids have been known to delay healing and cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. 

Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP. 

Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation. 

Bacterial Infections: Use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection. 

Viral Infections: Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). 

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. 

Adverse Reactions: 

The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients. 

CLICK HERE for full Prescribing Information

This meeting is non-CME/CE. 

Please note that meals and other items of value that Alcon provides to certain US licensed healthcare providers are subject to public disclosure in accordance with the transparency ("Sunshine") provision of the Patient Protection and Affordable Care Act.

As part of Alcon's commitment to complying with relevant legal requirements, we regret that we cannot provide meals for healthcare professionals licensed in Vermont. In addition, we may be unable to provide meals for healthcare professionals affiliated with state or federal institutions. If you are licensed in one of these states, affiliated with a state or federal institution, or are otherwise unable to accept a meal, other options may be available/  Please contact your Alcon sales representative for more information. Please note that attendance at this dinner meeting is limited to healthcare professionals only.